First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority tri (Q40662825)
Jump to navigation
Jump to search
scientific article published on 20 May 2016
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority tri |
scientific article published on 20 May 2016 |
Statements
1 reference
First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority tri (English)
1 reference
Ursula Vehling-Kaiser
1 reference
Clemens-Martin Wendtner
1 reference
Michael Hallek
1 reference
Jasmin Bahlo
1 reference
Anna-Maria Fink
1 reference
Raymonde Busch
1 reference
Gabor Kovacs
1 reference
Christian Maurer
1 reference
Elisabeth Lange
1 reference
Hubert Köppler
1 reference
Michael Kiehl
1 reference
Martin Sökler
1 reference
Rudolf Schlag
1 reference
Georg Köchling
1 reference
Christoph Plöger
1 reference
Michael Gregor
1 reference
Torben Plesner
1 reference
Kirsten Fischer
1 reference
Harmut Döhner
1 reference
Michael Kneba
1 reference
Wolfram Klapper
1 reference
Karl-Anton Kreuzer
1 reference
Sebastian Böttcher
1 reference
international group of investigators
1 reference
German CLL Study Group (GCLLSG)
1 reference
20 May 2016
1 reference
1 reference
17
1 reference
7
1 reference
928-942
1 reference
Identifiers
1 reference
1 reference